Cargando…
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
OBJECTIVE: To monitor the systemic immune responses of patients with multiple sclerosis (MS) under treatment with GNbAC1, a monoclonal antibody against the envelope protein of the MS- associated retrovirus, during a phase 2a trial. METHODS: We analyzed the composition of immune cell subsets and the...
Autores principales: | Zimmermann, Maria, Sanderson, Nicholas S.R., Rasenack, Maria, Lalive, Patrice H., Lang, Alois B., Curtin, Francois, Lindberg, Raija L.P., Kappos, Ludwig, Derfuss, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547879/ https://www.ncbi.nlm.nih.gov/pubmed/26380353 http://dx.doi.org/10.1212/NXI.0000000000000144 |
Ejemplares similares
-
The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2019) -
Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016) -
Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014) -
Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016) -
Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)